Previous 10 | Next 10 |
After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463. The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 20...
saengsuriya13/iStock via Getty Images Akebia Therapeutics ([[AKBA]] -3.8%) has been awarded a federal supply contract from the Department of Veterans Affairs. The contract awarded today is valued at $40.2M and runs for five years from July 01, 2021. The small-cap company, Akebia foc...
Cyclerion Therapeutics (CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics (AKBA) for the development and commercialization of praliciguat, an oral sGC stimulator.Under the terms of the agreement, Cyclerion is eligible to receive up to $585M in potential fu...
Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021 PR Newswire CAMBRIDGE, Mass. , June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impa...
Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...
Akebia Therapeutics (AKBA) and its collaborator, Otsuka Pharmaceutical, announce that the U.S. FDA accepted the New Drug Application ((NDA)) for vadadustat for review.The NDA looks at vadadustat for the treatment of anemia due to chronic kidney disease ((CKD)) in both adult patients on d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, investors, and I hope you enjoyed the long weekend! We’re getting right back into the swing of things with a look at the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.co...
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis - Vadadustat assigned PDUFA target action date of March 29, 2022 PR Newswir...
Akebia Therapeutics is one of three companies attempting to secure a first ever approval for a new type of therapy for Anemia due to Chronic Kidney Disease. Its hypoxia-inducible factor prolyl hydroxylase inhibitor ("HIF-PHI") looked a good bet for approval in patients on dialysis and...
3 Reddit Penny Stocks to Watch in May 2021 As May goes on, there are hundreds of penny stocks on Reddit that could be worth watching. However, just because a company is a Reddit penny stock , does not mean that it is worth buying. Rather, investors need to make sure to do their due ...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on May 9, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Akebia Therapeutics ...
2024-03-28 14:00:02 ET Ed Arce from H.C. Wainwright issued a price target of $6.00 for AKBA on 2024-03-28 12:08:00. The adjusted price target was set to $6.00. At the time of the announcement, AKBA was trading at $1.98. The overall price target consensus is at $7.00 with...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...